牛牛AI助手已提取核心信息
On March 1, 2024, Adial Pharmaceuticals, Inc. entered into a material definitive agreement with a holder of the company's existing warrants, resulting in the exercise of warrants for approximately 1,150,000 shares of common stock at $2.82 per share. This transaction, which closed on March 6, 2024, generated gross proceeds of about $3.5 million for Adial Pharmaceuticals, before accounting for placement agent fees and other expenses. In addition to the exercise of existing warrants, the company issued new unregistered Series C Warrants for the purchase of 2,300,000 shares of common stock. The company has agreed to file a registration statement for the resale of the new warrant shares within 45 days of the transaction's initial closing. The net proceeds from this transaction are intended for working capital and...Show More
On March 1, 2024, Adial Pharmaceuticals, Inc. entered into a material definitive agreement with a holder of the company's existing warrants, resulting in the exercise of warrants for approximately 1,150,000 shares of common stock at $2.82 per share. This transaction, which closed on March 6, 2024, generated gross proceeds of about $3.5 million for Adial Pharmaceuticals, before accounting for placement agent fees and other expenses. In addition to the exercise of existing warrants, the company issued new unregistered Series C Warrants for the purchase of 2,300,000 shares of common stock. The company has agreed to file a registration statement for the resale of the new warrant shares within 45 days of the transaction's initial closing. The net proceeds from this transaction are intended for working capital and other general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the transaction, receiving a cash fee, management fee, expense allowance, and legal fees, along with warrants to purchase 69,000 shares of common stock. The new warrants are exercisable immediately and will be valid for eighteen months from the date of issuance. The company has also committed to not issuing any additional common stock or equivalents for 30 days following the closing of the transaction.
2024年3月1日，Adial Pharmicals, Inc.与公司现有认股权证的持有人签订了重要的最终协议，最终以每股2.82美元的价格行使了约115万股普通股的认股权证。该交易于2024年3月6日完成，在不计入配售代理费和其他费用之前，为阿迪尔制药公司创造了约350万美元的总收益。除了行使现有认股权证外，该公司还发行了新的未注册C系列认股权证，用于购买2,300,000股普通股。该公司已同意在交易首次完成后的45天内提交转售新认股权证股份的注册声明。本次交易的净收益用于营运资金和其他一般公司用途。H.C. Wainwright & Co. 担任该交易的独家配售代理，获得现金费、管理费、支出补贴和律师费，以及购买69,000股普通股的认股权证。新的认股权证可立即行使，自发行之日起有效期为十八个月。该公司还承诺在交易完成后的30天内不发行任何额外的普通股或等价物。
2024年3月1日，Adial Pharmicals, Inc.与公司现有认股权证的持有人签订了重要的最终协议，最终以每股2.82美元的价格行使了约115万股普通股的认股权证。该交易于2024年3月6日完成，在不计入配售代理费和其他费用之前，为阿迪尔制药公司创造了约350万美元的总收益。除了行使现有认股权证外，该公司还发行了新的未注册C系列认股权证，用于购买2,300,000股普通股。该公司已同意在交易首次完成后的45天内提交转售新认股权证股份的注册声明。本次交易的净收益用于营运资金和其他一般公司用途。H.C. Wainwright & Co. 担任该交易的独家配售代理，获得现金费、管理费、支出补贴和律师费，以及购买69,000股普通股的认股权证。新的认股权证可立即行使，自发行之日起有效期为十八个月。该公司还承诺在交易完成后的30天内不发行任何额外的普通股或等价物。
有用
没用
